E. Ohman J or Asset Management AB Buys 8,200 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

E. Ohman J or Asset Management AB boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 23.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,981 shares of the company's stock after acquiring an additional 8,200 shares during the quarter. E. Ohman J or Asset Management AB owned 0.11% of Tarsus Pharmaceuticals worth $2,208,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its position in shares of Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the period. Sherbrooke Park Advisers LLC lifted its position in shares of Tarsus Pharmaceuticals by 7.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock worth $364,000 after buying an additional 443 shares during the period. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. Bank of New York Mellon Corp lifted its position in shares of Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after buying an additional 498 shares during the period. Finally, Swiss National Bank lifted its position in shares of Tarsus Pharmaceuticals by 1.2% during the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after buying an additional 600 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Trading Down 4.5%

Shares of Tarsus Pharmaceuticals stock traded down $1.94 during trading hours on Tuesday, hitting $41.17. The company's stock had a trading volume of 568,786 shares, compared to its average volume of 701,311. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The stock has a 50 day moving average of $45.89 and a 200 day moving average of $48.79. The company has a market capitalization of $1.73 billion, a PE ratio of -10.81 and a beta of 0.83. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on TARS shares. Jefferies Financial Group lifted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective for the company in a research report on Tuesday, May 27th. Oppenheimer started coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective for the company. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $66.67.

Insiders Place Their Bets

In related news, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at approximately $3,273,628.80. This trade represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $154,539.24. Following the transaction, the general counsel now owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. The trade was a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 over the last ninety days. 8.97% of the stock is currently owned by corporate insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.